BIOGEN INC. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
BIOGEN INC. (BIIB) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $293.90 million as of 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-02-05
- 2012-12-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $293.90M.
- 2012-09-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $290.30M.
- 2012-06-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $280.90M.
- 2012-03-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $269.90M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2012-12-31 | $293.90M 10-K · filed 2013-02-05 |
| 2012-09-30 | $290.30M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $280.90M 10-Q · filed 2012-10-25 |
| 2012-03-31 | $269.90M 10-Q · filed 2012-07-24 |
| 2011-12-31 | $151.00M 10-K · filed 2013-02-05 |
| 2011-09-30 | $125.90M 10-Q · filed 2012-10-25 |
| 2011-06-30 | $84.60M 10-Q · filed 2012-10-25 |
| 2011-03-31 | $82.40M 10-Q · filed 2012-07-24 |
| 2010-12-31 | $81.20M 10-K · filed 2013-02-05 |
| 2009-12-31 | $0.00 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |